Showing results (311-320 of 346) with videos related to

Sort By:
Pageof 35
Cancer|January 26, 2021
Treatment with pembrolizumab in programmed death ligand 1-positive recurrent glioblastoma: Results from the multicohort phase 1 KEYNOTE-028 trialDavid A Reardon, Tae Min Kim, Jean-Sebastien Frenel, et al.
Plos Neglected Tropical Diseases|February 10, 2022
Mouse models of Japanese encephalitis virus infection: A systematic review and meta-analysis using a meta-regression approachTehmina Bharucha, Ben Cleary, Alice Farmiloe, et al.
Brazilian Journal of Biology = Revista Brasleira De Biologia|February 29, 2024
Morpho-anatomical characterization and DNA barcoding of Artemesia vulgaris LD K Wahyuni, D T Indriati, M Ilham, et al.
The Journal of Infectious Diseases|April 18, 2015
The T-Cell Inhibitory Molecule Butyrophilin-Like 2 Is Up-regulated in Mild Plasmodium falciparum Infection and Is Protective During Experimental Cerebral MalariaKrishanthi S Subramaniam, Emily Spaulding, Emil Ivan, et al.
Biorxiv : the Preprint Server for Biology|February 24, 2023
Network-based elucidation of colon cancer drug resistance by phosphoproteomic time-series analysisGeorge Rosenberger, Wenxue Li, Mikko Turunen, et al.
JAMA Dermatology|February 4, 2026
Genotype-Phenotype Correlations in Recessive Dystrophic Epidermolysis Bullosa: A Systematic ReviewCara Heppell, Ping-Chen Hou, Aimée Longmore, et al.
Nature Communications|May 9, 2024
Network-based elucidation of colon cancer drug resistance mechanisms by phosphoproteomic time-series analysisGeorge Rosenberger, Wenxue Li, Mikko Turunen, et al.
Brazilian Journal of Biology = Revista Brasleira De Biologia|December 21, 2023
Unraveling the secrets of Eclipta alba (L.) Hassk.: a comprehensive study of morpho-anatomy and DNA barcodingD K Wahyuni, B F Yoku, S R Mukarromah, et al.
Frontiers in Oncology|September 27, 2018
Long-Term Outcomes Following Conventionally Fractionated Stereotactic Boost for High-Grade Gliomas in Close Proximity to Critical Organs at RiskMichael C Repka, Siyuan Lei, Lloyd Campbell, et al.
British Journal of Cancer|February 16, 2012
A phase I trial of pan-Bcl-2 antagonist obatoclax administered as a 3-h or a 24-h infusion in combination with carboplatin and etoposide in patients with extensive-stage small cell lung cancerA A Chiappori, M T Schreeder, M M Moezi, et al.
Pageof 35